Physician profile
Robin Stan
NPI 1912903048
$8,680.61
in general payments reported to CMS, 2019-2025
35 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $837 · 2021: $1,262 · 2022: $1,186 · 2023: $1,502 · 2024: $1,464 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,164.74 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,193.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $664.94 | 2022-2025 | Verquvo, Winrevair |
| Pfizer INC. | $642.05 | 2019-2025 | |
| Amgen INC. | $592.74 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.44 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $550.22 | 2020-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $502.31 | 2019-2025 | Wainua, Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $418.89 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $396.92 | 2022-2025 | |
| Abbott Laboratories | $280.79 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $244.46 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $237.31 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $174.25 | 2019-2023 | Amvuttra |
| Scpharmaceuticals INC. | $173.01 | 2023-2025 | |
| Akcea Therapeutics, INC. | $167.36 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $85.88 | 2022-2025 | Assure Wcd |
| Gilead Sciences, INC. | $80.07 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $78.94 | 2019 | |
| Bridgebio Pharma, INC. | $75.54 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, Ltd. | $70.33 | 2023 | Arcalyst |
| Boston Scientific Corporation | $57.05 | 2022-2024 | Watchman Access System, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $52.90 | 2019 | |
| Astellas Pharma US INC | $52.43 | 2020-2021 | |
| Edwards Lifesciences Corporation | $47.45 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $40.30 | 2021-2024 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $39.19 | 2023 | Optimizer |
| Liquidia Technologies, INC. | $30.78 | 2025 | Yutrepia |
| Heartflow, INC. | $28.88 | 2025 | |
| Irhythm Technologies, INC. | $24.09 | 2022 | |
| Vifor Pharma, INC. | $23.83 | 2020 | |
| Preventice Services, LLC | $21.98 | 2021 | |
| Glaxosmithkline, LLC. | $20.57 | 2021 | |
| Medtronic, INC. | $16.28 | 2021 | |
| Medtronic Vascular, INC. | $12.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Stan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.